

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<b>Application Number</b>	10/540,479
			<b>Filing Date</b>	May 10, 2006
			<b>First Named Inventor</b>	Steffen GOLETZ, et al.
			<b>Art Unit</b>	1643
			<b>Examiner Name</b>	Anne Gussow
(use as many sheets as necessary)			<b>Attorney Docket Number</b>	00056-0001-002
Sheet	1	of	3	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/AMG/	AA	5,739,277	04-14-1998	Presta, et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/AMG/	AB	DE 4329004	03-09-1995	Max Delbrueck Centrum	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/AMG/	AC	Karsten, et al., "A New Monoclonal Antibody (A78-G/A7) to the Tomsen-Friedenreich Pan-Tumor Antigen", <i>Hybridoma</i> , Vol. 14, No. 1, 1995, pages 37-44, XP009034408.		
/AMG/	AD	Panka, et al., "Variable Region Framework Differences Result in Decreased or Increased Affinity of Variant Anti-Digoxin Antibodies", <i>Proc. Natl. Acad. Sci. USA</i> , Vol 85, 3080-3084, May 1988.		
/AMG/	AE	Bagshawe, et al., "Antibody-Directed Enzyme Prodrug Therapy (ADEPT) for Cancer", <i>Expert Opin. Biol. Ther.</i> , 2004, Vol. 4, pages 1777-1789.		
/AMG/	AF	Abstract of Linardou, et al., "Deoxyribonuclease I (DNase I). A Novel Approach for Targeted Cancer Therapy", <i>Cell Biophys</i> , 1994, Vol. 24-25, pages 243-248.		
/AMG/	AG	Hsieh, et al., "Controlling Chemical Reactivity with Antibodies", <i>Science</i> , 1993, Vol. 260, pages 337-339.		
/AMG/	AH	Matzinger, "Tolerance, Danger, and the Extended Family", <i>Annual Review in Immunology</i> , 1994, Vol. 12, pages 991-1045.		
/AMG/	AI	Schneider, et al., "Thermotability of Membrane Protein Helix-Helix Interaction Elucidated by Statistical Analysis", <i>FEBS Lett</i> , 2002, Vol. 532, pages 231-236.		
/AMG/	AJ	Morrison, et al., "Complement Activation and Fc Receptor Binding by IgG", <i>Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man</i> , 1993, Mike Clark, Ed., pages 101-113.		

Examiner Signature	/Anne M. Gussow/	Date Considered	11/22/2010
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: September 9, 2010  (use as many sheets as necessary)			<b>Application Number</b>	10/540,479	
			<b>Filing Date</b>	May 10, 2006	
			<b>First Named Inventor</b>	Steffen GOLETZ, et al.	
			<b>Art Unit</b>	1643	
			<b>Examiner Name</b>	Anne Gussow	
<b>Sheet</b>	2	of	3	<b>Attorney Docket Number</b>	00056-0001-002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/AMG/	AK	Schlom, "Monoclonal Antibodies: They're More and Less Than You Think", <i>Molecular Foundations of Oncology</i> , 1991, Samuel Broder, Ed., pages 95-134.	
/AMG/	AL	Abstract of Euhus, et al., "Appraisal of Anti-Idiotypic Antibodies in the Treatment of Solid Tumors in Humans", <i>Surgery, Gynecology and Obstetrics</i> , 1992, Vol. 175(1), pages 89-96.	
/AMG/	AM	Green, et al., "Activation-Induced Cell Death in T Cells", <i>Immunological Reviews</i> , 2003, Vol. 193, pages 70-81.	
/AMG/	AN	M. Price, et al., "Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies Against the Mucin Mucin", <i>Tumor Biology, Karger, Base, CH</i> , Vol. 19, No. Suppl. 1, 1998, pages 1-20, XP002071245.	
/AMG/	AO	U. Jeschke, et al., "Expression of the Thomsen-Friedenreich Antigen and of its Putative Carrier Protein Mucin 1 in the Human Placenta and in Trophoblast Cells in Vitro", <i>Histochemistry and Cell Biology</i> , Vol. 117, No. 3, March 2002, pages 219-226, XP002290192.	
/AMG/	AP	F. Schneider, et al., "Overexpression of Sialyltransferase CMP-Sialic Acid: Galbeta1, 3Galnac-R Alpha6-Sialyltransferase is Related to Poor Patient Survival in Human Colorectal Carcinomas", <i>Cancer Research, American Association of Cancer Research</i> , Baltimore, MD, US, Vol. 61, No. 11, June 1, 2001, pages 4605-4611, XP002232470.	
/AMG/	AQ	Boel, et al., "Functional Human Monoclonal Antibodies of All Isotypes Constructed from Phage Display Library-Derived Single-Chain Fv Antibody Fragments", <i>J. Immunol. Methods</i> , Vol. 239, pages 153-166, 2000.	
/AMG/	AR	Brechbiel, et al., "Synthesis of 1(p-Isothiocyanatobenzyl) Derivatives of DTPA and EDTA Antibody Labeling and Tumor-Imaging Studies", <i>Inorg Chem</i> , Vol. 25, pages 2772-2781, 1986.	
/AMG/	AS	Chothia, et al., "The Predicted Structure of Immunoglobulin D1.3 and its Comparison with the Crystal Structure", <i>Science</i> , Vol. 233, pages 755-758, 1986.	
/AMG/	AT	Chothia, et al., "Conformations of Immunoglobulin Hypervariable Regions", <i>Nature</i> , Vol. 342, pages 877-883, 1989.	
/AMG/	AU	Chothia, et al., "Structural Repertoire of the Human V <sub>H</sub> Segments", <i>J. Mol. Biol.</i> , Vol. 227, pages 799-817, 1992.	
/AMG/	AV	Chothia, et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins", <i>J. Mol. Biol.</i> , Vol. 196, pages 901-917, 1987.	
/AMG/	AW	Herrera, et al., "Efficiency of Erythropoietin's Signal Peptide for HIV <sub>mn</sub> <sup>1-31</sup> gp120 Expression", <i>Biochem. Biophys. Res. Com.</i> , Vol. 273, pages 557-559, 2000.	

<b>Examiner Signature</b>	/Anne M. Gussow/	<b>Date Considered</b>	11/22/2010
---------------------------	------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: September 9, 2010  (use as many sheets as necessary)		<b>Application Number</b>	10/540,479
		<b>Filing Date</b>	May 10, 2006
		<b>First Named Inventor</b>	Steffen GOLETZ, et al.
		<b>Art Unit</b>	1643
		<b>Examiner Name</b>	Anne Gussow
		<b>Attorney Docket Number</b>	00056-0001-002
Sheet	3	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/AMG/	AX	Kozak, et al., "Nature of the Bifunctional Chelating Agent Used for Radioimmunotherapy with YTTRIUM-90 Monoclonal Antibodies: Critical Factors in Determining <i>in vivo</i> Survival and Organ Toxicity", <i>Cancer Res.</i> , Vol. 49, pages 2639-2644, 1989.	
/AMG/	AY	Liao, et al., "Design of Transgenes for Efficient Expression of Active Chimeric Proteins on Mammalian Cells", <i>Biotechnol Bioeng.</i> , Vol. 73, pages 313-323, 2000.	
/AMG/	AZ	Martin, et al., "Structural Families in Loops of Homologous Proteins: Automatic Classification, Modelling and Application to Antibodies", <i>J. Mol. Biol.</i> , Vol. 263, pages 800-815, 1996.	
/AMG/	BA	Nuttall, et al., "Design and Expression of Soluble CTLA-4 Variable Domain as a Scaffold for the Display of Functional Polypeptides", <i>Proteins</i> , Vol. 36, pages 217-227, 1999.	
/AMG/	BB	Nygren, et al., "Scaffolds for Engineering Novel Binding Sites in Proteins", <i>Cur. Opin. Struc. Biol.</i> , Vol. 7, pages 463-469, 1997.	
/AMG/	BC	Rooman, et al., "Amino Acid Sequence Templates Derived from Recurrent Turn Motifs in Proteins: Critical Evaluation of Their Predictive Power", <i>Protein Eng.</i> , Vol 3, pages 23-27, 1989.	
/AMG/	BD	Skerra, "Engineered Protein Scaffolds for Molecular Recognition", <i>J. Mol. Recog.</i> , Vol. 13, pages 167-187, 2000.	
/AMG/	BE	Stimmel, et al., "YTTRIUM-90 Chelation Properties of Tetraazatetraacetic Acid Macrocydes, Diethylenetriaminopentaacetic Acid Analogues, and a Novel Terpyridine Acyclic Chelator", <i>Bioconjug Chem.</i> , Vol. 6, pages 219-225, 1995.	
/AMG/	BF	Libyh, et al., "A Recombinant Human scFv Anti-RH(D) Antibody with Multiple Valences Using a C-Terminal Fragment of C4-Binding Protein", <i>Blood</i> , 90(10), pages 3978-3983, 1997.	
/AMG/	BG	Wu, et al., "Conformation of Complementarity Determining Region L1 Loop in Murine IgG A Light Chain Extends the Repertoire of Canonical Forms", <i>J. Mol. Biol.</i> , Vol. 229, pages 597-601, 1993.	

<b>Examiner Signature</b>	/Anne M. Gussow/	<b>Date Considered</b>	11/22/2010
---------------------------	------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.